Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea

Study by the consortium for improving survival of lymphoma

Byung Woog Kang, Sang Kyun Sohn, Joon Ho Moon, Yee Soo Chae, Jong Gwang Kim, Soo Jung Lee, Won Seog Kim, Je Jung Lee, Se Ryeon Lee, Keon Uk Park, Ho Sup Lee, Won Sik Lee, Jong Ho Won, Moo Rim Park, Jae Yong Kwak, Min Kyoung Kim, Hyo Jung Kim, Sung Yong Oh, Hye Jin Kang, Cheolwon Suh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalBlood Research
Volume49
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Mantle-Cell Lymphoma
Korea
Lymphoma
Survival
Disease-Free Survival
Incidence
Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Multivariate Analysis
Bone Marrow

Keywords

  • Chemotherapy
  • Epidemiology
  • Mantle cell lymphoma
  • Rituximab
  • Survival
  • Trend

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea : Study by the consortium for improving survival of lymphoma. / Kang, Byung Woog; Sohn, Sang Kyun; Moon, Joon Ho; Chae, Yee Soo; Kim, Jong Gwang; Lee, Soo Jung; Kim, Won Seog; Lee, Je Jung; Lee, Se Ryeon; Park, Keon Uk; Lee, Ho Sup; Lee, Won Sik; Won, Jong Ho; Park, Moo Rim; Kwak, Jae Yong; Kim, Min Kyoung; Kim, Hyo Jung; Oh, Sung Yong; Kang, Hye Jin; Suh, Cheolwon.

In: Blood Research, Vol. 49, No. 1, 01.01.2014, p. 15-21.

Research output: Contribution to journalArticle

Kang, BW, Sohn, SK, Moon, JH, Chae, YS, Kim, JG, Lee, SJ, Kim, WS, Lee, JJ, Lee, SR, Park, KU, Lee, HS, Lee, WS, Won, JH, Park, MR, Kwak, JY, Kim, MK, Kim, HJ, Oh, SY, Kang, HJ & Suh, C 2014, 'Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma', Blood Research, vol. 49, no. 1, pp. 15-21. https://doi.org/10.5045/br.2014.49.1.15
Kang, Byung Woog ; Sohn, Sang Kyun ; Moon, Joon Ho ; Chae, Yee Soo ; Kim, Jong Gwang ; Lee, Soo Jung ; Kim, Won Seog ; Lee, Je Jung ; Lee, Se Ryeon ; Park, Keon Uk ; Lee, Ho Sup ; Lee, Won Sik ; Won, Jong Ho ; Park, Moo Rim ; Kwak, Jae Yong ; Kim, Min Kyoung ; Kim, Hyo Jung ; Oh, Sung Yong ; Kang, Hye Jin ; Suh, Cheolwon. / Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea : Study by the consortium for improving survival of lymphoma. In: Blood Research. 2014 ; Vol. 49, No. 1. pp. 15-21.
@article{ee5fe5f43c1f419fab3891753b048d6f,
title = "Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma",
abstract = "Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9{\%} were men. A total of 105 patients (80.1{\%}) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7{\%}) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7{\%}) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5{\%}. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2{\%} and 35.1{\%}, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2{\%}). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7{\%}, while the event-free survival (EFS) was 39.7{\%}. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.",
keywords = "Chemotherapy, Epidemiology, Mantle cell lymphoma, Rituximab, Survival, Trend",
author = "Kang, {Byung Woog} and Sohn, {Sang Kyun} and Moon, {Joon Ho} and Chae, {Yee Soo} and Kim, {Jong Gwang} and Lee, {Soo Jung} and Kim, {Won Seog} and Lee, {Je Jung} and Lee, {Se Ryeon} and Park, {Keon Uk} and Lee, {Ho Sup} and Lee, {Won Sik} and Won, {Jong Ho} and Park, {Moo Rim} and Kwak, {Jae Yong} and Kim, {Min Kyoung} and Kim, {Hyo Jung} and Oh, {Sung Yong} and Kang, {Hye Jin} and Cheolwon Suh",
year = "2014",
month = "1",
day = "1",
doi = "10.5045/br.2014.49.1.15",
language = "English",
volume = "49",
pages = "15--21",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea

T2 - Study by the consortium for improving survival of lymphoma

AU - Kang, Byung Woog

AU - Sohn, Sang Kyun

AU - Moon, Joon Ho

AU - Chae, Yee Soo

AU - Kim, Jong Gwang

AU - Lee, Soo Jung

AU - Kim, Won Seog

AU - Lee, Je Jung

AU - Lee, Se Ryeon

AU - Park, Keon Uk

AU - Lee, Ho Sup

AU - Lee, Won Sik

AU - Won, Jong Ho

AU - Park, Moo Rim

AU - Kwak, Jae Yong

AU - Kim, Min Kyoung

AU - Kim, Hyo Jung

AU - Oh, Sung Yong

AU - Kang, Hye Jin

AU - Suh, Cheolwon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

AB - Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

KW - Chemotherapy

KW - Epidemiology

KW - Mantle cell lymphoma

KW - Rituximab

KW - Survival

KW - Trend

UR - http://www.scopus.com/inward/record.url?scp=84896998318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896998318&partnerID=8YFLogxK

U2 - 10.5045/br.2014.49.1.15

DO - 10.5045/br.2014.49.1.15

M3 - Article

VL - 49

SP - 15

EP - 21

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 1

ER -